eCOA in action: Podcast interview with iCardiac CEO, Alex Zapesochny
[audio src="https://healthbb.files.wordpress.com/2017/03/hbdew053-david-e-williams-interviews-icardiac-ceo-alex-zapesochny.mp3"][/audio]Electronic clinical outcome assessment (eCOA) platforms collect data from patients, clinicians and caregivers to make clinical trials more efficient and accurate. iCardiac Technologies, an innovative core lab where I am a board member, just introduced its QPoint eCOA platform to complement its existing cardiac safety and respiratory function product lines.In this podcast interview, iCardiac CEO Alex Zapesochny shares more about the launch.
- (0:11) What are some of the key trends you are following in clinical drug development?
- (1:04) You started with cardiac safety testing and then added pulmonary function testing. How do those fit together?
- (3:00) Now you have a new platform, QPoint. What is it, and why is it the next logical service?
- (4:44) For those who are less familiar with eCOA, what is it? And what are some of the challenges that are typically encountered?
- (7:09) Compliance is often an issue with patient reported outcomes. Do you address compliance with QPoint?
- (10:30) How important is eCOA for drug development? Is it a major change or incremental?
- (12:20) You have explained the move from cardiac safety to respiratory to eCOA. What can we expect next from iCardiac?
—
By healthcare business consultant David E. Williams, president of Health Business Group.